https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Hum. Immunol. 2009 May;70(5):331-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Hum. Immunol. 2009 May;70(5):331-92009-05-01 00:00:002019-02-15 09:19:12Melanoma vaccines: The problems of local immunosuppression
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Expert Opin Biol Ther 2009 May;9(5):539-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Expert Opin Biol Ther 2009 May;9(5):539-642009-05-01 00:00:002019-02-15 08:44:25Dendritic cells: therapy and imaging
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Expert Rev Vaccines 2009 May;8(5):567-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Expert Rev Vaccines 2009 May;8(5):567-762009-05-01 00:00:002019-02-15 08:44:24Novel strategies for improved cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / J. Immunother. 2009 May;32(4):363-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / J. Immunother. 2009 May;32(4):363-92009-05-01 00:00:002019-02-15 08:44:23Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / IDrugs 2009 May;12(5):297-301
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / IDrugs 2009 May;12(5):297-3012009-05-01 00:00:002019-02-15 08:44:21Antitumor vaccines, immunotherapy and the immunological constant of rejection
